Precision BioSciences reports cccDNA reduction in HBV study, activates second DMD site; updates deck

Precision BioSciences announced PBGENE-HBV data showing a 1-log reduction in cccDNA-derived transcripts and activation of a second FUNCTION-DMD clinical site.Key Highlights:Original SEC Filing: PRECISION BIOSCIENCES INC [ DTIL ] - 8-K - Jul. 01, 2026This is an AI-powered summary. It may contain ina…

Precision BioSciences announced PBGENE-HBV data showing a 1-log reduction in cccDNA-derived transcripts and activation of a second FUNCTION-DMD clinical site.

Key Highlights:

Updated corporate deck posted to investor site with ELIMINATE-B liver biopsy data showing direct elimination of cccDNA and a 1-log reduction in cccDNA-derived transcripts.
Company targets a program update by year-end 2026 for PBGENE-HBV and initial safety data for PBGENE-DMD.
Activated a second clinical site at Washington University School of Medicine for the FUNCTION-DMD trial evaluating PBGENE-DMD in Duchenne muscular dystrophy.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.